About Inactive C-alpha-formylglycine-generating enzyme 2
Inactive C-alpha-formylglycine-generating enzyme 2 (SUMF2) is a protein
from Homo sapiens identified by UniProt accession
Q8NBJ7, 301 residues long.
MolForge cross-references it against 0 known binders and
42 disease associations.
Target properties
| Protein name | Inactive C-alpha-formylglycine-generating enzyme 2 |
|---|
| UniProt accession | Q8NBJ7 |
|---|
| Gene | SUMF2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 301 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (42)
Diseases linked to this target (Open Targets).
- Multiple sulfatase deficiency · score 0.33
- serine measurement · score 0.31
- amino acid measurement · score 0.31
- neurodegenerative disease · score 0.29
- serum alanine aminotransferase measurement · score 0.21
- blood protein measurement · score 0.19
- body height · score 0.18
- threonine measurement · score 0.15
- erythrocyte count · score 0.13
- glomerular filtration rate · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8NBJ7-F1 | alphafold | PREDICTED | 90.81 | — |
Amino-acid sequence (301 residues)
MARHGLPLLP LLSLLVGAWL KLGNGQATSM VQLQGGRFLM GTNSPDSRDG DGPVREATVK PFAIDIFPVT NKDFRDFVRE KKYRTEAEMF GWSFVFEDFV SDELRNKATQ PMKSVLWWLP VEKAFWRQPA GPGSGIRERL EHPVLHVSWN DARAYCAWRG KRLPTEEEWE FAARGGLKGQ VYPWGNWFQP NRTNLWQGKF PKGDKAEDGF HGVSPVNAFP AQNNYGLYDL LGNVWEWTAS PYQAAEQDMR VLRGASWIDT ADGSANHRAR VTTRMGNTPD SASDNLGFRC AADAGRPPGE L
Explore Inactive C-alpha-formylglycine-generating enzyme 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets